KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Common Equity (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Common Equity for 17 consecutive years, with $52.8 billion as the latest value for Q4 2025.

  • Quarterly Common Equity rose 10.71% to $52.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.8 billion through Dec 2025, up 10.71% year-over-year, with the annual reading at $52.8 billion for FY2025, 10.71% up from the prior year.
  • Common Equity hit $52.8 billion in Q4 2025 for Abbott Laboratories, up from $51.0 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $52.8 billion in Q4 2025 to a low of -$15.8 billion in Q2 2024.
  • Historically, Common Equity has averaged $8.8 billion across 5 years, with a median of $158.5 million in 2022.
  • Biggest five-year swings in Common Equity: soared 32114.42% in 2022 and later tumbled 21987.5% in 2024.
  • Year by year, Common Equity stood at -$11.8 billion in 2021, then soared by 309.01% to $24.7 billion in 2022, then tumbled by 126.32% to -$6.5 billion in 2023, then soared by 832.84% to $47.7 billion in 2024, then rose by 10.71% to $52.8 billion in 2025.
  • Business Quant data shows Common Equity for ABT at $52.8 billion in Q4 2025, $51.0 billion in Q3 2025, and $264.0 million in Q2 2025.